tert-butyl ((1s,4s)-4-((1,3-dioxoisoindolin-2-yl)methyl)cyclohexyl)carbamate | 364385-65-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: tert-butyl ((1s,4s)-4-((1,3-dioxoisoindolin-2-yl)methyl)cyclohexyl)carbamate
• CAS: 364385-65-9
• 化学式: C₂₀H₂₆N₂O₄
• 分子量: 358.437
• InChiKey: JCOXNNQYKUFUFH-OKILXGFUSA-N

物化性质

• 沸点：
  502.7±19.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.37
• 重原子数：
  26.0
• 可旋转键数：
  3.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  75.71
• 氢给体数：
  1.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  tert-butyl ((1s,4s)-4-((1,3-dioxoisoindolin-2-yl)methyl)cyclohexyl)carbamate 在 palladium on activated charcoal 盐酸 、 氢气 、 sodium cyanoborohydride 、 一水合肼 、 溶剂黄146 、 三乙胺 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 乙酸乙酯 、 异丙醇 为溶剂， 反应 206.75h， 生成 N²-[cis-4-({[4-bromo-2-(trifluoromethoxy)benzyl]amino}methyl)cyclohexyl]-N⁴-methylquinazoline-2,4-diamine dihydrochloride
  参考文献：
  名称：

  Identification of 4-amino-2-cyclohexylaminoquinazolines as metabolically stable melanin-concentrating hormone receptor 1 antagonists

  摘要：

  The optimization of the distance between two key pharmacophore features within our first hit compounds la and 2a led to the identification of a new class of potent non-peptidic antagonists for the MCH-R1, based around 4-amino-2-cyclohexylamino-quinazolines. In particular, ATC0065 (2c), N-2-[cis-4-({2-[4-Bromo-2-(trifluoromethoxy)phenyl]ethyl}amino)cyclohexyl]-N-4,N-4-dimethylquinazoline-2,4-diamine dihydrochloride, bound with high affinity to the MCH-R1 (IC50 value of 16 nM) and showed good metabolic stability in liver microsomes from human and rat. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.12.052
• 作为产物：
  描述：

  cis-4-(tert-butoxycarbonylamino)cyclohexanecarboxylic acid methyl ester 在 lithium aluminium tetrahydride 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 乙醚 、 甲苯 为溶剂， 反应 62.0h， 生成 tert-butyl ((1s,4s)-4-((1,3-dioxoisoindolin-2-yl)methyl)cyclohexyl)carbamate
  参考文献：
  名称：

  Identification of 4-amino-2-cyclohexylaminoquinazolines as metabolically stable melanin-concentrating hormone receptor 1 antagonists

  摘要：

  The optimization of the distance between two key pharmacophore features within our first hit compounds la and 2a led to the identification of a new class of potent non-peptidic antagonists for the MCH-R1, based around 4-amino-2-cyclohexylamino-quinazolines. In particular, ATC0065 (2c), N-2-[cis-4-({2-[4-Bromo-2-(trifluoromethoxy)phenyl]ethyl}amino)cyclohexyl]-N-4,N-4-dimethylquinazoline-2,4-diamine dihydrochloride, bound with high affinity to the MCH-R1 (IC50 value of 16 nM) and showed good metabolic stability in liver microsomes from human and rat. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.12.052

文献信息

• Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
  申请人：Albers J. Ronald

  公开号：US20060287344A1

  公开（公告）日：2006-12-21

  Provided herein are Aminopurine Compounds having the following structure: wherein R 1 , R 2 and and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

  本文提供的是具有以下结构的氨基嘌呤化合物：其中R1、R2和R3的定义如本文所述，以及包含有效量氨基嘌呤化合物的组合物和用于治疗或预防癌症、心血管疾病、肾脏疾病、自身免疫疾病、炎症性疾病、黄斑变性、缺血再灌注损伤、疼痛和相关综合征、与疾病相关的消耗、石棉相关疾病、肺动脉高压或可通过抑制JNK通路治疗或预防的疾病的方法，包括向需要治疗的患者施用有效量的氨基嘌呤化合物。
• HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
  申请人：Albers Ronald J.

  公开号：US20090275564A1

  公开（公告）日：2009-11-05

  Provided herein are Aminopurine Compounds having the following structure: wherein R 1 , R 2 and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

  本文提供了具有以下结构的氨基嘌呤化合物：其中R1、R2和R3的定义如本文所述，包含有效量氨基嘌呤化合物的组合物，以及治疗或预防癌症、心血管疾病、肾脏疾病、自身免疫疾病、炎症性疾病、黄斑变性、缺血再灌注损伤、疼痛和相关综合症、与疾病相关的消耗、石棉相关疾病、肺动脉高压或可通过抑制JNK途径治疗或预防的疾病的方法，包括向需要治疗的患者注射有效量的氨基嘌呤化合物。
• Methods of treatment and prevention using haloaryl substituted aminopurines
  申请人：Bennett L. Brydon

  公开号：US20080021048A1

  公开（公告）日：2008-01-24

  Provided herein are Aminopurine Compounds having the following structure: wherein R 1 , R 2 and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

  本文提供了具有以下结构的氨基嘌呤化合物：其中R1、R2和R3的定义如本文所述，包含有效量的氨基嘌呤化合物的组合物以及用于治疗或预防癌症、心血管疾病、肾脏疾病、自身免疫疾病、炎症性疾病、黄斑变性、缺血再灌注损伤、疼痛和相关综合症、疾病相关消耗、石棉相关疾病、肺动脉高压或通过抑制JNK通路可治疗或预防的疾病的方法，包括向需要治疗的患者施用有效量的氨基嘌呤化合物。
• METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HALOARYL SUBSTITUTED AMINOPURINES OR COMPOSITIONS THEREOF
  申请人：Albers Ronald J.

  公开号：US20090312320A1

  公开（公告）日：2009-12-17

  Provided herein are Aminopurine Compounds having the following structure: wherein R 1 , R 2 and and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

  本文提供具有以下结构的氨基嘌呤化合物：其中R1、R2和R3如下定义，包含有效量的氨基嘌呤化合物的组合物以及治疗或预防癌症、心血管疾病、肾脏疾病、自身免疫疾病、炎症性疾病、黄斑变性、缺血再灌注损伤、疼痛和相关综合症、疾病相关消耗、石棉相关疾病、肺动脉高压或可通过抑制JNK通路治疗或预防的疾病的方法，包括向需要的患者施用有效量的氨基嘌呤化合物。
• METHODS OF MODULATING INFLAMMATORY CELL RECRUITMENT AND GENE EXPRESSION USING HALOARYL SUBSTITUTED AMINOPURINES
  申请人：Bennett Brydon L.

  公开号：US20100249066A1

  公开（公告）日：2010-09-30

  Provided herein are Aminopurine Compounds having the following structure: wherein R 1 , R 2 and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

  本文提供了具有以下结构的氨基嘌呤化合物：其中R1、R2和R3如下定义，包括有效量的氨基嘌呤化合物的组合物以及治疗或预防癌症、心血管疾病、肾脏疾病、自身免疫病、炎症性疾病、黄斑变性、缺血再灌注损伤、疼痛和相关综合征、疾病相关消耗、石棉相关疾病、肺动脉高压或可通过抑制JNK途径治疗或预防的疾病的方法，包括向需要治疗的患者中施用有效量的氨基嘌呤化合物。